Literature DB >> 34357463

Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis.

M S Sinto1, Shaji Thomas2, S Kannan3.   

Abstract

EGFR-targeted therapies are reported to yield modest effect in OSCC. Activation of NFκB signaling is considered as molecular driver of EGFR inhibitor resistance in various cancers. In this scenario, present study focused on the molecular crosstalk between EGFR and NFκB signaling pathways and its therapeutic importance in OSCC. The EGFR- NFκB p65 co-expressed human OSCC cell lines UPCI:SCC066, UPCI:SCC040 and UM-SCC083B were used for in vitro studies. Recombinant human EGF, siRNAs, Western blot and qRT-PCR were used to dissect the molecular crosstalk between EGFR-NFκB signaling pathways in OSCCs. The effect of NFκB p65 knockdown on cancer hallmarks was studied by respective functional assays and RNA-Seq analysis was performed to identify the differentially expressed genes upon NFκB p65 knockdown. Gefitinib and Bay 11-7085 combination treatment was done to study the chemotherapeutic potential of EGFR- NFκB axis. Significant positive correlation between EGFR and NFκB p65 expression was observed in Head and Neck TCGA data set. EGFR induction or knockdown respectively stimulate or impair the NFκB signaling in EGFR- NFκB p65 co-expressed OSCC cell lines. NFκB p65 knockdown causes apoptosis and suppresses the viability, colony formation, migration, invasion, and spheroid formation. Using RNA-seq analysis, we identified PIK3CD as the NFκB target gene, which is commonly involved in these functions. Gefitinib and Bay 11-7085 combination treatment was found to be useful in chemosensitizing the Gefitinib-resistant OSCC cells by capitulating the EGFR- NFκB signaling axis. Combination treatment using Gefitinib and Bay 11-7085 enhanced the apoptosis and reduced cell viability and colony formation in a synergistic way. Our data demonstrated that EGFR-NFκB signaling axis plays a key role in the pathogenesis of OSCCs. Therefore, simultaneous therapeutic intervention of these pathways may be a good alternative approach for the management of OSCCs.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  EGFR; Knockdown; Molecular crosstalk; NFκB; OSCC

Mesh:

Substances:

Year:  2021        PMID: 34357463     DOI: 10.1007/s12032-021-01557-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  44 in total

Review 1.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

2.  Global patterns and trends in cancers of the lip, tongue and mouth.

Authors:  Adalberto Miranda-Filho; Freddie Bray
Journal:  Oral Oncol       Date:  2020-01-25       Impact factor: 5.337

3.  Global Epidemiology of Head and Neck Cancers: A Continuing Challenge.

Authors:  Bhawna Gupta; Newell W Johnson; Narinder Kumar
Journal:  Oncology       Date:  2016-06-01       Impact factor: 2.935

Review 4.  The role of inflammation in head and neck cancer.

Authors:  Marcelo Bonomi; Alexis Patsias; Marshall Posner; Andrew Sikora
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 5.  Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy.

Authors:  Jun Ling; Raj Kumar
Journal:  Cancer Lett       Date:  2012-03-17       Impact factor: 8.679

6.  Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.

Authors:  C Alberti; P Pinciroli; B Valeri; R Ferri; A Ditto; K Umezawa; M Sensi; S Canevari; A Tomassetti
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 9.867

Review 7.  The diverse and complex roles of NF-κB subunits in cancer.

Authors:  Neil D Perkins
Journal:  Nat Rev Cancer       Date:  2012-01-19       Impact factor: 60.716

8.  Histological and molecular aspects of oral squamous cell carcinoma (Review).

Authors:  César Rivera; Bernardo Venegas
Journal:  Oncol Lett       Date:  2014-04-29       Impact factor: 2.967

Review 9.  Changing Trends in oral cancer - a global scenario.

Authors:  Neha Gupta; Ritu Gupta; Arun Kumar Acharya; Basavaraj Patthi; Venkatesh Goud; Somanath Reddy; Anshul Garg; Ashish Singla
Journal:  Nepal J Epidemiol       Date:  2016-12-31

Review 10.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.